

The Medical Letter[®]

on Drugs and Therapeutics

Volume 63

October 4, 2021

ISSUE No.
1634

IN THIS ISSUE

Influenza Vaccine for 2021-2022p 153

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 63 (Issue 1634)

October 4, 2021

Take CME Exams

▶ Influenza Vaccine for 2021-2022

Annual vaccination against influenza A and B viruses is recommended for everyone ≥ 6 months old without a contraindication.¹ Available influenza vaccines for the 2021-2022 season are listed in Table 2.

Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Lower-than-usual rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures, and travel restrictions.² According to the CDC, reduced immunity due to low influenza virus activity since March 2020 may result in an early and possibly severe influenza season in 2021-2022.¹

TIMING – In the US, vaccination against influenza should be offered by the end of October and continue to be offered as long as influenza is circulating in the community. In most adults, serum antibody levels peak about two weeks after vaccination. Early vaccination (i.e., in July or August) may result in suboptimal immunity before the end of the influenza season, especially in older adults.³ Children who require 2 doses (see Table 2, footnote 2) should receive the first dose as early as possible so that the second dose can be given by the end of October. Vaccination of persons with suspected or laboratory-confirmed COVID-19 should be postponed until they are no longer acutely ill and no longer require isolation.

Table 1. 2021-2022 Influenza Vaccine Composition¹

Egg-Based Vaccines

A/Victoria/2570/2019 (H1N1)pdm09-like
A/Cambodia/e0826360/2020 (H3N2)-like
B/Washington/02/2019 (Victoria lineage)-like
B/Phuket/3073/2013 (Yamagata lineage)-like

Cell Culture-Based and Recombinant Vaccines

A/Wisconsin/588/2019 (H1N1)pdm09-like
A/Cambodia/e0826360/2020 (H3N2)-like
B/Washington/02/2019 (Victoria lineage)-like
B/Phuket/3073/2013 (Yamagata lineage)-like

1. All influenza vaccines available in the US for the 2021-2022 influenza season are quadrivalent. Trivalent influenza vaccines are not available for the 2021-2022 influenza season.

Key Points: Influenza Vaccine for 2021-2022

- ▶ Annual vaccination against influenza A and B viruses is recommended for everyone ≥ 6 months old without a contraindication.
- ▶ Vaccination should be offered by the end of October and continue to be offered as long as influenza viruses are circulating in the community.
- ▶ All influenza vaccines available in the US this season are quadrivalent; they contain two influenza A and two influenza B virus antigens.
- ▶ Influenza vaccination reduces the risk of influenza illness and can lower the risk of influenza-related hospitalizations and death.
- ▶ Use of a recombinant, high-dose, or adjuvanted vaccine can improve immune responses in older adults.
- ▶ Pregnant women should be vaccinated against influenza without regard to the trimester of pregnancy.
- ▶ Persons with a history of egg allergy can receive any age-appropriate influenza vaccine.

COMPOSITION – Influenza A viruses are the main cause of influenza-related morbidity and mortality, particularly in infants and older adults. Children are more likely than adults to become infected with influenza B.

All influenza vaccines available in the US this season are quadrivalent; they contain two influenza A and two influenza B virus antigens (see Table 1).

EFFECTIVENESS – Influenza vaccination reduces the incidence of laboratory-confirmed influenza and can reduce the risk of serious complications and death associated with influenza illness in children and adults.⁴⁻⁷ The effectiveness of the seasonal influenza vaccine in preventing influenza illness depends on several factors, including the match between the vaccine and circulating strains and the immunologic response of the recipient. Vaccine effectiveness is greatest when the match is close, but even when it is suboptimal, vaccination can still substantially reduce the risk of influenza-related hospitalization and death.^{8,9}

LIVE-ATTENUATED VACCINE – *FluMist Quadrivalent*, the intranasal live-attenuated influenza vaccine, is FDA-approved for use in healthy nonpregnant persons 2-49 years old (see Table 2, footnote 17 for contraindications).

Table 2. Seasonal Influenza Vaccines for 2021-2022

Vaccine	Available Formulations ¹	Recommended Age ²	Cost ³
Standard-Dose Inactivated Quadrivalent (IIV4)			
<i>Afluria Quadrivalent</i> (Seqirus) ⁴⁻⁶	0.25 mL syringe	6-35 months	\$18.40
	0.5 mL syringe	≥3 years	18.40
	5 mL multidose vial ⁷	≥6 months ⁸	16.90
<i>Fluarix Quadrivalent</i> (GSK) ^{4,9}	0.5 mL syringe	≥6 months	17.40
<i>FluLaval Quadrivalent</i> (GSK) ⁴	0.5 mL syringe	≥6 months	17.40
<i>Fluzone Quadrivalent</i> (Sanofi) ⁴	0.5 mL syringe	≥6 months ¹⁰	18.10
	0.5 mL vial	≥6 months ¹⁰	18.10
	5 mL multidose vial ⁷	≥6 months ¹⁰	16.80
High-Dose Inactivated Quadrivalent (IIV4)			
<i>Fluzone High-Dose Quadrivalent</i> (Sanofi) ^{4,11}	0.7 mL syringe	≥65 years	80.90
Adjuvanted Inactivated Quadrivalent (aIIV4; standard-dose)			
<i>Fluad Quadrivalent</i> (Seqirus) ^{4,12,13}	0.5 mL syringe	≥65 years	57.60
Cell Culture-Based Inactivated Quadrivalent (ccIV4; standard-dose)			
<i>Flucelvax Quadrivalent</i> (Seqirus) ¹⁴	0.5 mL syringe	≥2 years	25.60
	5 mL multidose vial ⁷	≥2 years	24.30
Recombinant Quadrivalent (RIV4)			
<i>Flublok Quadrivalent</i> (Sanofi) ¹⁵	0.5 mL syringe	≥18 years	56.60
Live-Attenuated Quadrivalent (LAIV4)			
<i>FluMist Quadrivalent</i> (AstraZeneca) ^{4,9,16,17}	0.2 mL intranasal sprayer ¹⁸	2-49 years	23.00

1. Single-dose vials and syringes are sold in boxes of 10. Multidose vials contain 10 doses.

2. Children 6 months to 8 years old who are being vaccinated for the first time, whose vaccination history is not known, or who have not received at least 2 lifetime doses of a trivalent or quadrivalent vaccine before July 1, 2021 should receive 2 doses at least 4 weeks apart. The first dose should be given as soon as possible after the vaccine becomes available so that the second dose can be given by the end of October. Children in this age group who received ≥2 doses of a trivalent or quadrivalent vaccine at any time before July 1, 2021 require only 1 dose.

3. Approximate WAC per dose. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource@ Monthly. September 5, 2021. Reprinted with permission by First Databank, Inc. All rights reserved. ©2021. www.fdbhealth.com/policies/drug-pricing-policy.

4. Prepared by propagation of virus in embryonated hen eggs.

5. May contain residual amounts of neomycin sulfate, polymyxin B, and hydrocortisone.

6. Delivery of *Afluria Quadrivalent* via the *Pharma Jet Stratis* needle-free injection system is FDA-licensed for persons 18-64 years old.

7. Contains ~25 mcg/0.5 mL dose of mercury; strong evidence shows no increased risk from exposure to vaccines containing mercury.

8. The dose is 0.25 mL for children 6-35 months old and 0.5 mL for those ≥3 years old.

9. May contain residual amounts of gentamicin sulfate and hydrocortisone.

10. The dose is either 0.25 mL or 0.5 mL for children 6-35 months old and 0.5 mL for those ≥3 years old.

11. Contains 60 mcg of hemagglutinin antigen from each strain, compared to 15 mcg in standard-dose inactivated vaccines.

12. Contains MF59, an oil-in-water emulsion of squalene oil.

13. May contain residual amounts of neomycin, kanamycin, and hydrocortisone.

14. Uses mammalian cells for replication rather than hen eggs.

15. Contains 45 mcg of hemagglutinin antigen from each strain, compared to 15 mcg in standard-dose inactivated vaccines. Contains no egg proteins.

16. Each 0.2-mL dose contains 10^{6.5}-10^{7.5} FFU (fluorescent focus units) of live-attenuated influenza virus reassortants from each strain.

17. Contraindicated for use in pregnant women, persons who are immunocompromised, persons with active communication between the CSF and oropharynx, nasopharynx, nose, or ear or any other cranial CSF leak, persons with cochlear implants, children 2-4 years old who have asthma or have had a wheezing episode within the previous 12 months, children or adolescents taking aspirin or salicylate-containing therapy, close contacts of severely immunocompromised persons who require a protected environment, or patients treated with oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir marboxil within the previous 17 days. Use of influenza antiviral drugs <2 weeks after administration of the intranasal live-attenuated vaccine could inhibit replication of the vaccine virus, reducing the vaccine's efficacy. Some medical conditions (e.g., renal impairment) may require a longer interval between the antiviral drug regimen and administration of *FluMist Quadrivalent*. Patients of any age with asthma may be at increased risk of wheezing after administration of *FluMist Quadrivalent*.

18. Each single-use sprayer delivers one 0.2-mL intranasal dose (given as 0.1 mL in each nostril). If nasal congestion that could impair vaccine delivery to the nasal mucosa is present, an injectable vaccine should be selected instead. If use of an injectable vaccine is unacceptable, influenza vaccination should be delayed.

OLDER ADULTS – Older adults may have weaker immunogenic responses to influenza vaccination than younger persons, and their antibody levels may decline more rapidly, decreasing vaccine effectiveness.¹⁰ In a recent trial in community-dwelling adults 65-82 years old, recombinant, high-dose, and adjuvanted vaccines improved humoral and cell-mediated immune responses compared to standard-dose inactivated vaccines.¹¹ Clinical trials comparing the three types of vaccines in older adults are lacking.

Recombinant Vaccine – *Flublok Quadrivalent*, a recombinant influenza vaccine produced without

the use of influenza virus or chicken eggs, contains 3 times the amount of antigen included in standard-dose inactivated influenza vaccines.

In a randomized, double-blind trial in 8604 adults ≥50 years old during the A/H3N2-predominant 2014-2015 season, the recombinant quadrivalent vaccine was 30% more effective than a nonadjuvanted standard-dose inactivated quadrivalent vaccine in preventing laboratory-confirmed influenza illness.¹²

High-Dose Vaccine – *Fluzone High-Dose Quadrivalent*, an inactivated vaccine that contains 4 times the

amount of antigen included in standard-dose inactivated influenza vaccines, is FDA-licensed for use in persons ≥ 65 years old.

In a randomized, double-blind trial in 31,989 adults ≥ 65 years old during 2 influenza seasons, a high-dose inactivated trivalent vaccine (*Fluzone High-Dose* – not available in 2021-2022) induced significantly greater antibody responses than a standard-dose inactivated trivalent vaccine and was 24% more effective in preventing laboratory-confirmed influenza illness.¹³ In several studies in adults ≥ 65 years old, a high-dose inactivated trivalent vaccine was associated with a reduced risk of respiratory-related and all-cause hospitalization and death compared to standard-dose inactivated trivalent vaccines.¹⁴⁻¹⁷

In a randomized trial in 5260 patients with high-risk cardiovascular disease, use of a high-dose inactivated trivalent vaccine over 3 influenza seasons did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations compared to standard-dose inactivated quadrivalent vaccines.¹⁸

Adjuvanted Vaccine – The adjuvanted inactivated influenza vaccine *Fluad Quadrivalent* is FDA-licensed for use in persons ≥ 65 years old. It contains MF59, an oil-in-water emulsion of squalene oil that increases the immune response by recruiting antigen-presenting cells to the injection site and promoting uptake of influenza virus antigens.

In a randomized trial in 7082 adults ≥ 65 years old, an adjuvanted inactivated trivalent vaccine (*Fluad* – not available in 2021-2022) elicited significantly greater antibody responses against all three influenza strains than a nonadjuvanted inactivated trivalent vaccine.¹⁹ In several trials, older adults who received an adjuvanted inactivated trivalent vaccine were less likely than those who received a nonadjuvanted inactivated trivalent vaccine to develop symptomatic influenza illness or to be hospitalized for influenza or pneumonia.²⁰⁻²²

PREGNANCY – The ACIP and the American College of Obstetricians and Gynecologists (ACOG) recommend that pregnant women be vaccinated against influenza without regard to the trimester of pregnancy.^{23,24} Vaccination protects pregnant women against influenza-associated illness, which can be especially severe during pregnancy, and protects their infants for up to the first 6 months after birth (influenza vaccines are not approved for use in infants < 6 months old).²⁵

Most studies have not found an association between influenza vaccination and adverse pregnancy outcomes, but data demonstrating the safety of vaccination during the first trimester are limited.²⁶ Pregnant women should not receive the live-attenuated vaccine.

EGG ALLERGY – Although most influenza vaccines contain trace amounts of egg protein (ovalbumin), numerous studies have demonstrated that patients with egg allergy are not at increased risk for a reaction to any influenza vaccine.²⁷ The recombinant vaccine (*Flublok Quadrivalent*) and the cell culture-based vaccine (*Flucelvax Quadrivalent*) do not contain egg protein.

The ACIP states that persons with egg allergy of any severity can receive any age-appropriate influenza vaccine, but those with a history of more severe egg allergy (angioedema, respiratory distress, light-headedness, recurrent vomiting, or requiring epinephrine or another emergency medical intervention) who receive an egg-based vaccine should be vaccinated in a medical setting (e.g., doctor's office or clinic) supervised by a clinician experienced in managing severe allergic reactions.¹

The Joint Task Force on Practice Parameters of the American Academy of Allergy Asthma and Immunology and the American College of Allergy Asthma and Immunology as well as the American Academy of Pediatrics state that no special precautions are necessary for patients with egg allergy of any severity.²⁸

IMMUNOCOMPROMISED PERSONS – The live-attenuated influenza vaccine should not be used in immunocompromised persons. Inactivated and recombinant vaccines are generally considered safe for use in such persons, but the immune response may be reduced. In two randomized trials in solid-organ transplant recipients, the high-dose vaccine induced significantly greater immune responses than standard-dose vaccines.^{29,30} Separation in time of influenza vaccination from an immunocompromising intervention might be considered.

USE WITH OTHER VACCINES – Any influenza vaccine can be given at the same time as a COVID-19 vaccine, but the vaccines should be administered at different sites. **Inactivated** and **recombinant** influenza vaccines can be administered concomitantly or sequentially with live or other inactivated or recombinant vaccines. The **live-attenuated** influenza vaccine can be given

simultaneously with inactivated or other live vaccines; other live vaccines not administered simultaneously should be given at least 4 weeks later. Use of a nonadjuvanted influenza vaccine could be considered in persons receiving an **adjuvanted** non-influenza vaccine (e.g., *Shingrix*, *Heplisav-B*); coadministration of *Shingrix* and a nonadjuvanted inactivated quadrivalent influenza vaccine has not been associated with a decrease in the immunogenicity of either vaccine.³¹

USE WITH INFLUENZA ANTIVIRALS – Use of oseltamivir (*Tamiflu*, and generics) or zanamivir (*Relenza*) within 48 hours before, peramivir (*Rapivab*) within 5 days before, or baloxavir marboxil (*Xofluza*) within 17 days before or <2 weeks after administration of the intranasal live-attenuated influenza vaccine could inhibit replication of the vaccine virus, reducing the vaccine's efficacy.

ADVERSE EFFECTS – Influenza vaccination has been associated with Guillain-Barré syndrome, but the absolute risk is very low (about 1-2 additional cases per million persons vaccinated), and influenza infection itself has been associated with the syndrome (about 17 cases per million influenza infection encounters).^{32,33}

Except for soreness at the injection site, adverse reactions to **inactivated** influenza vaccines are uncommon. In clinical trials, *Fluzone High-Dose* (trivalent formulation) caused more injection-site reactions than standard-dose influenza vaccines. Pain and tenderness at the injection site also occurred more frequently with *Fluad* (adjuvanted trivalent) than with a nonadjuvanted vaccine. Delivery of *Afluria* by needle-free jet injector has resulted in more mild to moderate local reactions than delivery of a vaccine by standard needle and syringe.

The most common adverse reactions associated with the **live-attenuated** vaccine are runny nose, nasal congestion, fever, and sore throat. The vaccine can increase the risk of wheezing, especially in children <5 years old with recurrent wheezing and in persons of any age with asthma. Persons who receive the live-attenuated vaccine may shed the vaccine-strain virus for a few days after vaccination, but person-to-person transmission has been rare, and serious illness resulting from transmission has not been reported. Nevertheless, persons who care for severely immunocompromised patients in protected environments should not receive the live-attenuated vaccine or should avoid contact with such patients for 7 days after receiving it. ■

1. LA Grohskopf et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. *MMWR Recomm Rep* 2021; 70(No. RR-5):1. Available at: <https://bit.ly/3BPK9dS>. Accessed September 9, 2021.
2. World Health Organization. Influenza update N° 399. August 2, 2021. Available at: <https://bit.ly/3l4TXcY>. Accessed September 9, 2021.
3. JM Ferdinands et al. Waning vaccine effectiveness against influenza-associated hospitalizations among adults, 2015-2016 to 2018-2019, United States hospitalized adult influenza vaccine effectiveness network. *Clin Infect Dis* 2021; 73:726.
4. C Arriola et al. Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. *Clin Infect Dis* 2017; 65:1289.
5. B Flannery et al. Influenza vaccine effectiveness against pediatric deaths: 2010-2014. *Pediatrics* 2017; 139:e20164244.
6. AP Campbell et al. Effect of vaccination on preventing influenza-associated hospitalizations among children during a severe season associated with B/Victoria viruses, 2019-2020. *Clin Infect Dis* 2021; 73:e947.
7. S Garg et al. Influenza vaccine reduces risk of severe outcomes among adults hospitalized with influenza A(H1N1) pdm09, FluServ-NET, 2013-2018. ID Week, Washington, DC, October 2-6, 2019. Abstract 898. Available at: <https://bit.ly/3lIEr6e>. Accessed September 9, 2021.
8. M Darvishian et al. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. *Lancet Infect Dis* 2014; 14:1228.
9. MA Rolfes et al. Effects of influenza vaccination in the United States during the 2017-2018 influenza season. *Clin Infect Dis* 2019; 69:1845.
10. B Young et al. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. *Vaccine* 2017; 35:212.
11. BJ Cowling et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. *Clin Infect Dis* 2020; 71:1704.
12. LM Dunkle et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. *N Engl J Med* 2017; 376:2427.
13. CA DiazGranados et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med* 2014; 371:635.
14. S Gravenstein et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. *Lancet Respir Med* 2017; 5:738.
15. DK Shay et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. *J Infect Dis* 2017; 215:510.
16. JKH Lee et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. *Expert Rev Vaccines* 2018; 17:435.
17. Y Young-Xu et al. High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012/13 to 2014/2015. *Euro Surveill* 2020; 25:1900401.

18. O Vardeny et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial. *JAMA* 2021; 325:39.
19. SE Frey et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. *Vaccine* 2014; 32:5027.
20. PG Van Buynder et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. *Vaccine* 2013; 31:6122.
21. F Lapi et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. *Expert Rev Vaccines* 2019; 18:663.
22. KW McConeghy et al. Cluster-randomized trial of adjuvanted vs. non-adjuvanted trivalent influenza vaccine in 823 U.S. nursing homes. *Clin Infect Dis* 2020 September 4 (epub).
23. CDC. Addressing concerns pregnant people might have about influenza vaccine safety. September 3, 2021. Available at: <https://bit.ly/3jDkTyg>. Accessed September 9, 2021.
24. ACOG Committee Opinion No. 732: influenza vaccination during pregnancy. *Obstet Gynecol* 2018; 131:e109.
25. MG Thompson et al. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: a multi-country retrospective test negative design study, 2010-2016. *Clin Infect Dis* 2019; 68:1444.
26. A Mehrabadi et al. Association of maternal influenza vaccination during pregnancy with early childhood health outcomes. *JAMA* 2021; 325:2285.
27. M Greenhawt et al. Administration of influenza vaccines to egg allergic recipients: a practice parameter update 2017. *Ann Allergy Asthma Immunol* 2018; 120:49.
28. American Academy of Allergy Asthma & Immunology. Egg allergy and the flu vaccine. August 11, 2021. Available at: <https://bit.ly/3yV2uUl>. Accessed September 9, 2021.
29. Y Natori et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. *Clin Infect Dis* 2018; 66:1698.
30. AG L'Huillier et al. Cell-mediated immune responses after influenza vaccination of solid organ transplant recipients: secondary outcomes analyses of a randomized controlled trial. *J Infect Dis* 2020; 221:53.
31. TF Schwarz et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. *J Infect Dis* 2017; 216:1352.
32. JC Kwong et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. *Lancet Infect Dis* 2013; 13:769.
33. LL Polakowski et al. Chart-confirmed Guillain-Barré syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010. *Am J Epidemiol* 2013; 178:962.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
 The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:
 Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:
 To reproduce any portion of this issue,
 please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
 1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:
 E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.

Get Connected:  

Copyright 2021. ISSN 1523-2859

